Lilly, BI Get Tentative FDA Approval for Insulin Basaglar as an NDA

Generic Line
Eli Lilly and Boehringer Ingelheim have won tentative FDA approval for their insulin product Basaglar, which is considered the biosimilar of a Sanofi product in Europe but is being reviewed as its own NDA in the United States.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00